Epilepsy drugs may elevate suicide risk, FDA says

01/31/2008 | Wall Street Journal (free content), The · Forbes

The FDA has warned that common anti-epileptic drugs may increase the risk of suicide. The agency's review of clinical studies of 11 drugs -- including Pfizer's Lyrica and Johnson & Johnson's Topamax -- showed that patients using the drugs were twice as likely to have suicidal behavior as those who took a placebo. Pfizer said it hasn't found evidence of an increased risk of suicide-related events in Lyrica. Johnson & Johnson said the Topamax label already carries a discussion about suicide attempts.

View Full Article in:

Wall Street Journal (free content), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN